{"entity":{"id":442,"slug":"merck-kgaa","name":"Merck KGaA","type":"company","role":"German pharmaceutical company","description":null,"imageUrl":null,"createdAt":"2026-04-08T17:50:15.562Z","updatedAt":"2026-04-08T17:50:15.562Z"},"electedOffice":null,"significance":{"score":3,"components":{"totalFindings":0,"connectionDegree":2,"recentFindings90d":0,"activeResearchJobs":0,"goblinAttributions":1,"recentSyntheses90d":0,"moneyFlowChainsTotal":0,"closedLoopMemberships":0,"moneyFlowHopsRecent90d":0},"computedAt":"2026-10-15T01:32:54.708Z"},"facts":[{"id":10662,"text":"Merck KGaA filed filing with the SEC on 2023-01-27. Accession number: N/A.","confidence":"secondary","dateOccurred":"2023-01-27","source":null},{"id":21018,"text":"Search scope note: No lobbying disclosures found for \"Merck KGaA\" in automated database search as of 2026-04-23. This reflects search coverage limits, not confirmed absence from public record.","confidence":"inferential","dateOccurred":null,"source":null},{"id":21017,"text":"Search scope note: No corporate registrations found for \"Merck KGaA\" in automated database search as of 2026-04-23. This reflects search coverage limits, not confirmed absence from public record.","confidence":"inferential","dateOccurred":null,"source":null},{"id":21016,"text":"Search scope note: No usaspending contracts found for \"Merck KGaA\" in automated database search as of 2026-04-23. This reflects search coverage limits, not confirmed absence from public record.","confidence":"inferential","dateOccurred":null,"source":null}],"connections":[{"id":867,"relationshipType":"partner","description":"Joint partnership through EMD Digital for Syntropy cancer research platform in 2020","confidence":"confirmed","firstDocumented":null,"lastDocumented":null,"other":{"id":17,"name":"Palantir Technologies","slug":"palantir-technologies","type":"company"}},{"id":19009,"relationshipType":"investor","description":"Jacobs' 2020 financial disclosure shows millions invested in pharmaceutical company Merck.","confidence":"primary","firstDocumented":"2020","lastDocumented":null,"other":{"id":10989,"name":"Sara Jacobs","slug":"congress-j000305","type":"person"}},{"id":18843,"relationshipType":"donor","description":"In May 2024, Ross received campaign donations from the CEO of Merck (among other pharmaceutical CEOs), and Pharmaceuticals/Health Products was a top industry donor at $101,295.","confidence":"primary","firstDocumented":"2024","lastDocumented":null,"other":{"id":11019,"name":"Deborah K. Ross","slug":"congress-r000305","type":"person"}},{"id":15510,"relationshipType":"investor","description":"The foundation disbursed over $500 million to pharmaceutical companies including Merck for vaccine development, while the Gates Foundation Trust held equity positions in pharmaceutical companies creating a documented conflict of interest.","confidence":"primary","firstDocumented":"2021","lastDocumented":null,"other":{"id":982,"name":"Bill & Melinda Gates Foundation","slug":"bill-melinda-gates-foundation","type":"institution"}},{"id":15232,"relationshipType":"former professional role","description":"Before becoming Chief Scientific Adviser, Vallance was President of Research and Development at Merck KGaA (the German pharmaceutical company), where he worked from 2012 to 2017.","confidence":"primary","firstDocumented":"2012","lastDocumented":null,"other":{"id":4225,"name":"Patrick Vallance","slug":"patrick-vallance","type":"person"}}],"contradictions":[],"permalink":"https://www.goblinhouse.net/entity/merck-kgaa","timelineUrl":"https://www.goblinhouse.net/entity/merck-kgaa/timeline"}